Evaluates pilavapadin's impact on spasticity endpoints in central nervous system injury models, suggesting promising therapeutic potential.
To evaluate the effects of the adapter protein-2 associated kinase 1 (AAK1) inhibitor pilavapadin on spasticity endpoints in preclinical models of central nervous system injury.
No takes yet. Share an insight, caveat, or question.
Gopinathan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: